Our Services
Medical Information
Helpful Resources
Published on: 9/15/2026
Combining berberine with metformin may lower blood sugar more than either alone, which raises the risk of hypoglycemia, stomach upset, and diarrhea, so it is generally not considered safe without medical supervision. Berberine can also interfere with liver enzymes that process many prescription drugs, and it should be avoided during pregnancy, breastfeeding, and in infants. Dosing, timing, kidney function, and your other medications all change the picture, so there are several important factors to consider before you start or stop anything, explained in full below. If you are noticing shakiness, dizziness, unusual fatigue, digestive changes, or blood sugar readings that swing higher or lower than normal, those signals deserve attention now rather than later. Take a free, instant, online symptom check to see what your symptoms could mean and get clear guidance on the next steps to discuss with your doctor.
Last reviewed for medical accuracy: 09/14/2026
Is Berberine Safe to Take with Metformin for Blood Sugar?
Managing blood sugar often involves a combination of prescription medications, lifestyle changes, and sometimes dietary supplements. Berberine—a plant-derived compound—has gained attention for its potential to help control glucose levels. If you’re already taking metformin, you might wonder: Is it safe to add berberine? Below, we review the evidence on berberine side effects and safety, consider how it interacts with metformin, and offer practical guidance.
Metformin and berberine both help lower blood sugar, but they do so through slightly different mechanisms:
Metformin
Berberine
Because they both boost AMPK activity, combining them can have an additive effect on lowering blood sugar. That can be good—but it also raises questions about safety and side effects.
Several clinical trials and meta-analyses have looked at berberine’s effects on blood sugar, often comparing it directly to metformin or using it alongside standard therapies:
A 2015 meta-analysis (Journal of Ethnopharmacology) reviewed 14 randomized controlled trials:
A 2019 trial (Phytomedicine) gave 84 type 2 diabetic patients either metformin, berberine, or both for 12 weeks:
A small 2020 study (Nutrients) observed improved lipid profiles when berberine was added to metformin, hinting at broader metabolic benefits.
While these findings are promising, most studies are short (8–16 weeks) and involve modest sample sizes. Long-term data on combined use are still limited.
When considering any supplement, know the common side effects and safety cautions. Here’s what to watch for with berberine:
Common Berberine Side Effects
Less Common but Important
Key Safety Points
Additive Gastrointestinal Effects
Hypoglycemia (Low Blood Sugar)
Lactic Acidosis Concern
Drug Interactions
To maximize benefits and minimize risks, consider these practical steps:
Talk to Your Healthcare Provider
Monitor Closely
Timing and Dosing
Watch for Warning Signs
Lifestyle Still Matters
If you experience any of the following, get professional help right away:
For non-urgent concerns, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker before deciding on next steps.
Combining berberine with metformin can offer an extra edge in controlling blood sugar, thanks to their complementary mechanisms. Most studies report good tolerability, but you do need to watch for:
Berberine side effects and safety are generally acceptable when you follow dosing guidelines and monitor carefully. Always start low, go slow, and keep your healthcare provider in the loop.
Note: This information is not a substitute for professional medical advice. If you have serious or life-threatening concerns, speak to a doctor immediately.
(References)
* Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008 May;57(5):712-7. doi: 10.1016/j.metabol.2008.01.013. PMID: 18442638; PMCID: PMC2410097.
* Wang H, Zhu C, Ying Y, Luo L, Huang D, Luo Z. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. Oncotarget. 2018 Feb 9;9(11):10135-10146. doi: 10.18632/oncotarget.20807. 2017 Sep 11. PMID: 29515798; PMCID: PMC5839379.
* Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacol Res. 2021 May;167:105484. doi: 10.1016/j.phrs.2021.105484. 2021 Mar 24. PMID: 33771699.
* Wang Z, Nie K, Su H, Tang Y, Wang H, Xu X, Dong H. Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome. Phytomedicine. 2021 Oct;91:153654. doi: 10.1016/j.phymed.2021.153654. 2021 Jul 12. PMID: 34333328.
* Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021 Aug 18;18(1):171. doi: 10.1186/s12978-021-01207-7. 2021 Aug 18. PMID: 34407851; PMCID: PMC8371888.
* Hedayati N, Oskouei Z, Tabeshpour J, Naeini MB. Berberine and lycopene as alternative or add-on therapy to metformin and statins, a review. Eur J Pharmacol. 2021 Dec 15;913:174590. doi: 10.1016/j.ejphar.2021.174590. 2021 Nov 18. PMID: 34801530.
* Kodi T, Praveen S, Paka SK, Sankhe R, Gopinathan A, Krishnadas N, Kishore A. Neuroprotective Effects of Metformin and Berberine in Lipopolysaccharide-Induced Sickness-Like Behaviour in Mice. Adv Pharmacol Pharm Sci. 2024;2024:8599268. doi: 10.1155/2024/8599268. 2024 Sep 21. PMID: 39346967; PMCID: PMC11438515.
* Shobnam N, Ratley G, Saksena S, Yadav M, Chaudhary PP, Sun AA, Howe KN, Gadkari M, Franco LM, Ganesan S, McCann KJ, Hsu AP, Kanakabandi K, Ricklefs S, Lack J, Yu W, Similuk M, Walkiewicz MA, Gardner DD, Barta K, Tullos K, Myles IA. Topical Steroid Withdrawal Is a Targetable Excess of Mitochondrial NAD. J Invest Dermatol. 2025 Aug;145(8):1953-1968.e14. doi: 10.1016/j.jid.2024.11.026. 2025 Mar 14. PMID: 40088241; PMCID: PMC12286752.
* Li N, Chen QW, Gong XL, Liu F, Zhang B, Wang QS, Zhang H, Han JJ. Metformin and berberine synergistically improve NAFLD via the AMPK-SREBP1-FASN signaling pathway. Sci Rep. 2025 Aug 11;15(1):29400. doi: 10.1038/s41598-025-15495-7. 2025 Aug 11. PMID: 40790070; PMCID: PMC12339966.
* Li Z, Wang N, Li X, Xie Y, Dou Z, Xin H, Lin Y, Si Y, Feng T, Wang G. Thyroid cancer: From molecular insights to therapy (Review). Oncol Lett. 2025 Nov;30(5):520. doi: 10.3892/ol.2025.15266. 2025 Sep 10. PMID: 40980146; PMCID: PMC12447069.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.